Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation

• Status: Completed
• Trial end date: 2013-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the levels of loteprednol etabonate (LE) in tear fluid following a single topical instillation of LE ophthalmic gel 0.5% formulation to healthy volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bausch & Lomb Incorporated
• Treatments: Loteprednol Etabonate

Criteria

Inclusion Criteria:

• Subjects must be healthy volunteers with physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings.

• Subjects must have a best-corrected visual acuity of 20/20 or better in each eye.

• Subjects must have no active ocular disease or allergic conjunctivitis.

• Subjects must have a Schirmer test (without anesthesia) of ≥ 10mm in 5 minutes.

• Subjects must not be using any topical ocular medications or systemic medication other than acetaminophen.

• Male subjects or female subjects who are not of childbearing potential. Female subjects are considered to not be of childbearing potential if they are postmenopausal for at least 12 months or permanently sterilized (eg, tubal occlusion, hysterectomy, bilateral salpingectomy)

Exclusion Criteria:

• Subjects having an intraocular pressure less than 5 mmHg or greater than 22 mmHg or any type of glaucoma.

• Subjects with a history of ocular trauma, infection, or inflammation within the last 3 months.

• Subjects having any contraindication to the use of, or known sensitivity or allergy to, the study drug(s) or their components.

• Subjects wearing contact lenses on the day of Visit 2 and/or Visit 3 of the study

• Subjects having, at the Investigator's discretion, the presence of any significant illness that could be expected to interfere with the study.